Northwest Medical Weight Loss Clinic
9696 Gordon Drive · Highland, IN 46322
4.8(16 Google reviews · 11 in past year)
TelehealthAccepts insurance
Listing updated Oct 2, 2026
Optimum Endocrine Care: Nidal Hasan, MD
Optimum Endocrine Care: Nidal Hasan, MD · 9013 Indianapolis Boulevard · Highland, IN 46322
4.6· 178 Google reviews
Listing updated October 2, 2026
Retatrutide outlook for this practice
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
Care described on the practice's website
- Medically supervised weight loss
- Endocrine / metabolic care
About this practice
Optimum Endocrine Care in Highland, Indiana, is an endocrinology practice led by Nidal Hasan, MD, whom its website describes as a board-certified endocrinologist and internist with more than two decades of experience. The site lists a Highland office and says virtual visits are offered, with a focus on diabetes and hormone-related conditions. Google shows a 4.6-star rating across 178 reviews dating back to 2021, 22 in the past year, with the staff, a caring approach and providers' knowledge cited most often.
Services & access
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Yes |
| Cash pay accepted | — |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Review activity
★ 4.6
Google rating · 178 reviews
22
reviews in the past year (avg ★ 4.3)
4
reviews mention weight loss
Counts computed by RetaMaps from public Google reviews; most recent review 2026-09-23. Read the reviews themselves on the practice's Google listing.
What patients say
Rated ★4.6 across 178 Google reviews. Of the 100 reviews we analyzed, 88 (88%) are positive (4–5★) and 11 (11%) are negative (1–2★).
What patients like
- Friendly, helpful staff30 reviews
- Feeling listened to25 reviews
- Knowledgeable, professional providers13 reviews
- Easy scheduling and communication9 reviews
Common complaints
- Scheduling or communication problems7 of 11 negative
- Staff or front-desk issues5 of 11 negative
- Billing, pricing or insurance problems3 of 11 negative
5★
85
4★
3
3★
1
2★
1
1★
10
Most recent Google reviews
Amber F.★★★★★2026-09-23So far my experience has been great , I know he treated my sister and cured her of cancer so I'd say I am going to stick with him !
Zois R.★★★★★2026-09-18Very professional and personable. Made me feel very comfortable and Dr was very knowledgeable and experienced and explained everything. I was very happy.
Eddie2842 S.★★★★★2026-09-09Thanks Guys!
Linda H.★★★★★2026-08-31Doctor great nurse. Tammy very great very nice
anthony b.★★★★★2026-08-16Thank you, Doctor Hasan, for helping me through this journey of me being diabetic. Your knowledge and guidance have helped me tremendously.
Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.
Clinicians
- Optimum Endocrine Care: Nidal Hasan, MD
Nearby providers in Highland
Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
- Development
- Phase 3 complete
- FDA status
- Submission planned — Q1 2027 (Lilly guidance)
- Availability
- Not commercially available
- Access routes
- Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs